The purpose of this study is to achieve a better understanding of clinical characteristics, treatment patterns and clinical outcomes of participants with moderate-to-severe plaque psoriasis (PsO) as well as their unmet medical needs and disease burden in real-world setting in China.
Study Type
OBSERVATIONAL
Enrollment
3,506
Local Institution - 0002
Beijing, Beijing Municipality, China
Local Institution - 0001
Nanjing, Jiangsu, China
Distribution of demographic characteristics: Age
Time frame: Baseline
Distribution of demographic characteristics: Sex
Time frame: Baseline
Distribution of clinical characteristics: Height
Time frame: Baseline
Distribution of clinical characteristics: Weight
Time frame: Baseline
Distribution of clinical characteristics: Body Mass Index (BMI)
Time frame: Baseline
Distribution of clinical characteristics: Disease duration
Time frame: Baseline
Distribution of clinical characteristics: Severity of PsO
Time frame: Baseline
Distribution of clinical characteristics: Comorbidities
Time frame: Baseline
Treatment patterns: Drug categories treated during study period
Time frame: Up to 4 Years
Treatment patterns: Drug names treated during study period
Time frame: Up to 4 Years
Treatment patterns: Medication dosage
Time frame: Up to 4 Years
Treatment patterns: Drug's administration frequency
Time frame: Up to 4 Years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Treatment patterns: Reason for treatment change during study period
Time frame: Up to 4 Years
Treatment patterns: Treatment duration of each drug during study period
Time frame: Up to 4 Years
Treatment patterns: Treatment sequence
Time frame: Up to 4 Years
Treatment patterns: Change of treatment pattern
Time frame: Up to 4 Years
Number of participants achieving Body Surface Area of <3% during study period
Time frame: Up to 4 Years
Psoriasis Area and Severity (PASI) Index
Time frame: Up to 4 Years
Number of participants achieving Static Physicians Global Assessment (sPGA) of 0/1 during study period
Time frame: Up to 4 Years
Healthcare resource utilization (HCRU)
HCRU will include visit date, visit type, cost, inpatient visits, outpatient visits, length of stay, and direct medical cost.
Time frame: Up to 4 Years
Evaluation of patient reported outcome measure: Patients' global assessment of disease activity (PtGA)
PtGA of psoriasis is an indicator of disease severity of PsO measured using a single-item, five- point scale ranging from 0 (clear) to 4 (severe). Category labels include 'clear', 'almost clear', 'mild', 'moderate' and 'severe'.
Time frame: Up to 4 Years
Evaluation of patient reported outcome measure: Dermatology life quality index (DLQI)
DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult participants with skin diseases such as eczema, psoriasis, acne and viral warts. Each item has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30 and higher scores indicate greater HRQoL impairment.
Time frame: Up to 4 Years
Evaluation of patient reported outcome measure: EQ-5D-3L
The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. For each dimension, participant is asked to choose one of the 3 levels (no problems, some problems, and extreme problems) to indicate his/her health state. This decision results into a 1-digit number and the digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state.
Time frame: Up to 4 Years